Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer's disease

Stock Information for Actinogen Medical Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Actinogen Medical Limited

Actinogen provides pivotal Alzheimer's trial enrolment update and other business news

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.